Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/104382
Title: Evaluation of aminoglycoside and non-aminoglycoside compounds for stop-codon readthrough therapy in four lysosomal storage diseases
Author: Gómez Grau, Marta
Garrido Fernández, Elena
Cozar, Mónica
Rodríguez Sureda, Víctor
Domínguez, Carmen
Arenas Solà, Concepción
Gatti, Richard A
Cormand Rifà, Bru
Grinberg Vaisman, Daniel Raúl
Vilageliu i Arqués, Lluïsa
Keywords: Lisosomes
Antibiòtics
Lysosomes
Antibiotics
Issue Date: 19-Aug-2015
Publisher: Public Library of Science (PLoS)
Abstract: Nonsense mutations are quite prevalent in inherited diseases. Readthrough drugs could provide a therapeutic option for any disease caused by this type of mutation. Geneticin (G418) and gentamicin were among the first to be described. Novel compounds have been generated, but only a few have shown improved results. PTC124 is the only compound to have reached clinical trials. Here we first investigated the readthrough effects of gentamicin on fibroblasts from one patient with Sanfilippo B, one with Sanfilippo C, and one with Maro- teaux-Lamy. We found that ARSB activity (Maroteaux-Lamy case) resulted in an increase of 2 - 3 folds and that the amount of this enzyme within the lysosomes was also increased, after treatment. Since the other two cases (Sanfilippo B and Sanfilippo C) did not respond to gentamicin, the treatments were extended with the use of geneticin and five non-aminogly- coside (PTC124, RTC13, RTC14, BZ6 and BZ16) readthrough compounds (RTCs). No recovery was observed at the enzyme activity level. However, mRNA recovery was observed in both cases, nearly a two-fold increase for Sanfilippo B fibroblasts with G418 and around 1.5 fold increase for Sanfilippo C cells with RTC14 and PTC124. Afterwards, some of the products were assessed through in vitro analyses for seven mutations in genes responsible for those diseases and, also, for Niemann-Pick A/B. Using the coupled tran- scription/translation system (TNT), the best results were obtained for SMPD1 mutations with G418, reaching a 35% recovery at 0.25 μ g/ml, for the p.W168X mutation. The use of COS cells transfected with mutant cDNAs gave positive results for most of the mutations with some of the drugs, although to a different extent. The higher enzyme activity recovery, of around two-fold increase, was found for gentamicin on the ARSB p.W146X mutation. Our results are promising and consistent with those of other groups. Further studies of novelcompounds are necessary to find those with more consistent efficacy and fewer toxic effects
Note: Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0135873
It is part of: PLoS One, 2015, vol. 10, num. 8, p. e0135873
Related resource: https://doi.org/10.1371/journal.pone.0135873
URI: http://hdl.handle.net/2445/104382
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (Genètica, Microbiologia i Estadística)

Files in This Item:
File Description SizeFormat 
654125.pdf2.44 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons